Sally H Ibbotson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/328070/publications.pdf

Version: 2024-02-01

228	6,922	66343	76900
papers	citations	42 h-index	74 g-index

235	235	235	4645
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Depth Penetration of Light into Skin as a Function of Wavelength from 200 to 1000 nm. Photochemistry and Photobiology, 2022, 98, 974-981.	2.5	88
2	Athena: Specialty Certificate Examination Case in Photodermatology. Clinical and Experimental Dermatology, 2022, , .	1.3	0
3	British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022. British Journal of Dermatology, 2022, 187, 295-308.	1.5	9
4	Development of a Predictive Monte Carlo Radiative Transfer Model for Ablative Fractional Skin Lasers. Lasers in Surgery and Medicine, 2021, 53, 731-740.	2.1	6
5	Broad-spectrum abnormal localized photosensitivity syndrome. Journal of the American Academy of Dermatology, 2021, 85, 1298-1300.	1.2	3
6	Role of Hypotaurine in Protection against UVAâ€Induced Damage in Keratinocytes. Photochemistry and Photobiology, 2021, 97, 353-359.	2.5	4
7	A new approach to actinic folliculitis: prophylactic narrowband ultraviolet B phototherapy. Clinical and Experimental Dermatology, 2021, 46, 675-679.	1.3	3
8	Daylight photodynamic therapy for actinic keratosis: Is it affected by the British weather?. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 157-158.	1.5	1
9	A photodynamic therapy patient survey: Realâ€life experience from two regional services. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 226-229.	1.5	0
10	Extreme Exposure to Filtered Farâ€UVC: A Case Study^{â€}. Photochemistry and Photobiology, 2021, 97, 527-531.	2.5	45
11	Minimal, superficial DNA damage in human skin from filtered farâ€ultraviolet C. British Journal of Dermatology, 2021, 184, 1197-1199.	1.5	24
12	Narrowband ultraviolet B phototherapy is associated with a reduction in topical corticosteroid and clinical improvement in atopic dermatitis: a historical inception cohort study. Clinical and Experimental Dermatology, 2021, 46, 1067-1074.	1.3	5
13	Fluorescence and thermal imaging of non-melanoma skin cancers before and during photodynamic therapy. Photodiagnosis and Photodynamic Therapy, 2021, 34, 102327.	2.6	0
14	Global verification of a model for determining daylight photodynamic therapy dose. Photodiagnosis and Photodynamic Therapy, 2021, 34, 102260.	2.6	1
15	Computer Modeling Indicates Dramatically Less DNA Damage from Farâ€UVC Krypton Chloride Lamps (222) Tj ETQq1 1 0.784314 rgBT	2.5	7
16	A novel automatic <scp>3D</scp> stitching algorithm for optical coherence tomography angiography and its application in dermatology. Journal of Biophotonics, 2021, 14, e202100152.	2.3	8
17	Photodiagnostic services in the UK and Republic of Ireland: a British Photodermatology Group Workshop Report. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2448-2455.	2.4	3
18	A Randomised Assessor Blinded Comparison of Low Irradiance and Conventional Irradiance Photodynamic Therapy for Superficial Basal Cell Carcinoma and Bowenâ€™s Disease. British Journal of Dermatology, 2021, , .	1.5	1

#	Article	IF	Citations
19	Phototherapy for atopic eczema. The Cochrane Library, 2021, 2021, CD013870.	2.8	9
20	Quantitative analysis of topical treatments in atopic dermatitis: unexpectedly low use of emollients and strong correlation of topical corticosteroid use both with depression and concurrent asthma. British Journal of Dermatology, 2020, 182, 1017-1025.	1.5	13
21	Is there an optimal irradiation dose for photodynamic therapy: 37 J cm â^'2 or 75 J cm â^'2 ?. British Journal of Dermatology, 2020, 182, 1287-1288.	1.5	1
22	Research Techniques Made Simple: Experimental UVR Exposure. Journal of Investigative Dermatology, 2020, 140, 2099-2104.e1.	0.7	5
23	æ¹¿ç–¹æ‚£è€…ä½¿ç”¨åšå°‘æ¶¦è‚¤ä¹³è†¸ä»¥åŠæŠ‘éƒ—å’Œçš®è‚¤ä¹³è†ä½¿ç”¨ä¹‹é—´çš„å…³è” British Journal of D	1.5	0
24	How much emollient and steroid cream do eczema patients use, and the link between depression and steroid cream use. British Journal of Dermatology, 2020, 182, e143.	1.5	0
25	SmartPDTÂ®: Smartphone enabled real-time dosimetry via satellite observation for daylight photodynamic therapy. Photodiagnosis and Photodynamic Therapy, 2020, 31, 101914.	2.6	8
26	Shedding light on the itch of cholestasis. British Journal of Dermatology, 2019, 181, 1117-1117.	1.5	0
27	å±€éƒ¨ PDT ä¸è‰¯ä½œç”¨çš„ç®¡ç†. British Journal of Dermatology, 2019, 180, e130.	1.5	0
28	Measuring Daylight: A Review of Dosimetry in Daylight Photodynamic Therapy. Pharmaceuticals, 2019, 12, 143.	3.8	13
29	Management of adverse effects of topical PDT. British Journal of Dermatology, 2019, 180, e114.	1.5	1
30	Ultraviolet radiation exposure during daylight Photodynamic Therapy. Photodiagnosis and Photodynamic Therapy, 2019, 27, 19-23.	2.6	9
31	The effects of sunscreen use and window glass on daylight photodynamic therapy dosimetry. British Journal of Dermatology, 2019, 181, 220-221.	1.5	4
32	Tomato Phytonutrients Balance UV Response: Results from a Double-Blind, Randomized, Placebo-Controlled Study. Skin Pharmacology and Physiology, 2019, 32, 101-108.	2.5	24
33	Daylight photodynamic therapy: patient willingness to undertake home treatment. British Journal of Dermatology, 2019, 181, 834-835.	1.5	8
34	Factors influencing pain and efficacy of topical photodynamic therapy: a retrospective study. British Journal of Dermatology, 2019, 180, 205-206.	1.5	5
35	Adverse effects of topical photodynamic therapy: a consensus review and approach to management. British Journal of Dermatology, 2019, 180, 715-729.	1.5	49
36	British Association of Dermatologists and British Photodermatology Group guidelines for topical photodynamic therapy 2018. British Journal of Dermatology, 2019, 180, 730-739.	1.5	51

#	Article	IF	Citations
37	Efficacy of localized hand and foot phototherapy: a review of patients treated in a teaching hospital setting. Clinical and Experimental Dermatology, 2019, 44, 356-358.	1.3	0
38	Fieldâ€change actinic keratosis and immunosuppression: therapeutic options. British Journal of Dermatology, 2018, 178, 829-830.	1.5	1
39	A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy. British Journal of Dermatology, 2018, 179, 309-319.	1.5	44
40	Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin. Photochemical and Photobiological Sciences, 2018, 17, 773-780.	2.9	26
41	Menthol reduces phototoxicity pain in a mouse model of photodynamic therapy. Pain, 2018, 159, 284-297.	4.2	7
42	Irradiance, as well as body site and timing of readings, is important in determining ultraviolet A minimal erythema dose. British Journal of Dermatology, 2018, 178, 297-298.	1.5	2
43	Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in six European countries. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 757-762.	2.4	18
44	çª„æ³¢ UVB ç”¨äºŽé“¶å±‘ç—…æ²»ç——çš„è´¹ç”¨. British Journal of Dermatology, 2018, 179, e213-e213.	1.5	0
45	Cost of narrowband ultraviolet B for psoriasis. British Journal of Dermatology, 2018, 179, e199-e199.	1.5	0
46	å…‰åŠ¨åŠ›ç——æ³•æ²»ç——åŸºåº•ç»†èƒžç™Œ. British Journal of Dermatology, 2018, 179, e252-e252.	1.5	2
47	Photodynamic therapy for basal cell carcinoma. British Journal of Dermatology, 2018, 179, e237-e237.	1.5	0
48	Drug and chemical induced photosensitivity from a clinical perspective. Photochemical and Photobiological Sciences, 2018, 17, 1885-1903.	2.9	33
49	Optimizing photodynamic therapy regimens: variables in irradiation may influence outcomes. British Journal of Dermatology, 2018, 178, 1003-1003.	1.5	1
50	Are photosensitizing medications associated with increased risk of important erythemal reactions during ultraviolet B phototherapy?. British Journal of Dermatology, 2018, 179, 1184-1185.	1.5	8
51	A Perspective on the Use of NB-UVB Phototherapy vs. PUVA Photochemotherapy. Frontiers in Medicine, 2018, 5, 184.	2.6	49
52	Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis. British Journal of Dermatology, 2018, 179, 1277-1296.	1.5	34
53	Narrowband ultraviolet B treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments. British Journal of Dermatology, 2018, 179, 1148-1156.	1.5	19
54	A novel light source with tuneable uniformity of light distribution for artificial daylight photodynamic therapy. Photodiagnosis and Photodynamic Therapy, 2018, 23, 144-150.	2.6	9

#	Article	IF	Citations
55	Structural characterization on in vitro porcine skin treated by ablative fractional laser using optical coherence tomography. , 2018, , .		1
56	Structured Expert Consensus on Actinic Keratosis: Treatment Algorithm Focusing on Daylight PDT. Journal of Cutaneous Medicine and Surgery, 2017, 21, 3S-16S.	1.2	33
57	Shedding light on drug photosensitivity reactions. British Journal of Dermatology, 2017, 176, 850-851.	1.5	8
58	Phototherapy and photochemotherapy for polymorphic light eruption desensitization: a fiveâ€year case series review from a university teaching hospital. Photodermatology Photoimmunology and Photomedicine, 2017, 33, 225-227.	1.5	10
59	Daylight photodynamic therapy in Scotland. Scottish Medical Journal, 2017, 62, 48-53.	1.3	12
60	Polymorphic light eruption with severe abnormal phototesting sensitivity (<scp>PLESAPS</scp>). Photodermatology Photoimmunology and Photomedicine, 2017, 33, 326-328.	1.5	5
61	Use of illuminance as a guide to effective light delivery during daylight photodynamic therapy in the U.K.. British Journal of Dermatology, 2017, 176, 1607-1616.	1.5	21
62	A consensus on the use of daylight photodynamic therapy in the UK. Journal of Dermatological Treatment, 2017, 28, 360-367.	2.2	15
63	A Review of Photodiagnostic Investigations over 26 Years: Experience of the National Scottish Photobiology Service (1989â€“2015). Journal of the Royal College of Physicians of Edinburgh, The, 2017, 47, 345-350.	0.6	10
64	Narrowband UVB treatment is highly effective and causes a strong reduction in the use of steroid and other creams in psoriasis patients in clinical practice. PLoS ONE, 2017, 12, e0181813.	2.5	17
65	Ultraviolet A1 phototherapy: One center's experience. Indian Journal of Dermatology, Venereology and Leprology, 2017, 83, 60.	0.6	15
66	Characteristics of actinic prurigo in Scotland: 24 cases seen between 2001 and 2015. British Journal of Dermatology, 2016, 174, 1411-1414.	1.5	15
67	Can antioxidant-rich blackcurrant juice drink consumption improve photoprotection against ultraviolet radiation?. British Journal of Dermatology, 2016, 174, 1101-1103.	1.5	2
68	Allergic contact dermatitis to topical prodrugs used in photodynamic therapy. Photodermatology Photoimmunology and Photomedicine, 2016, 32, 320-322.	1.5	5
69	Filaggrin genotype does not determine the skin's threshold to UV-induced erythema. Journal of Allergy and Clinical Immunology, 2016, 137, 1280-1282.e3.	2.9	6
70	Patient satisfaction in the photodynamic therapy clinic. Photodermatology Photoimmunology and Photomedicine, 2016, 32, 44-47.	1.5	4
71	British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralenâ€“ultraviolet A therapy 2015. British Journal of Dermatology, 2016, 174, 24-55.	1.5	79
72	Practice when minimal phototoxic and minimal erythema doses are not determinable. Photodermatology Photoimmunology and Photomedicine, 2015, 31, 224-226.	1.5	2

#	Article	IF	Citations
73	Is photodynamic diagnostic flexible ureterorenoscopy suitable for a patient presenting with chronic actinic dermatitis?. Photodermatology Photoimmunology and Photomedicine, 2015, 31, 279-281.	1.5	1
74	Nrf2 Activation Protects against Solar-Simulated Ultraviolet Radiation in Mice and Humans. Cancer Prevention Research, 2015, 8, 475-486.	1.5	94
75	Predicted increased risk of squamous cell carcinoma induction associated with sunbed exposure habits. British Journal of Dermatology, 2015, 173, 201-208.	1.5	21
76	Loss-of-Function Mutations in the Gene Encoding Filaggrin Are Not Strongly Associated with Chronic Actinic Dermatitis. Journal of Investigative Dermatology, 2015, 135, 1919-1921.	0.7	6
77	Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin. Photodiagnosis and Photodynamic Therapy, 2015, 12, 630-639.	2.6	13
78	The effect of 222â€nm <scp>UVC</scp> phototesting on healthy volunteer skin: a pilot study. Photodermatology Photoimmunology and Photomedicine, 2015, 31, 159-166.	1.5	41
79	How should we diagnose and manage photosensitivity?. Journal of the Royal College of Physicians of Edinburgh, The, 2014, 44, 308-312.	0.6	2
80	Topical photodynamic therapy for nonâ€malignant skin conditions: experience from a university teaching hospital. Photodermatology Photoimmunology and Photomedicine, 2014, 30, 280-282.	1.5	2
81	Impact assessment of energy-efficient lighting in patients with lupus erythematosus: a pilot study. British Journal of Dermatology, 2014, 170, 694-698.	1.5	6
82	Photoallergic Contact Dermatitis. , 2014, , 85-114.		3
83	Review of an established UK home phototherapy service 1998â€“2011: improving access to a cost-effective treatment for chronic skin disease. Public Health, 2014, 128, 317-324.	2.9	39
84	Drug-Induced Photosensitivity. Dermatologic Clinics, 2014, 32, 363-368.	1.7	50
85	The acute inflammatory response to photodynamic therapy. British Journal of Dermatology, 2013, 169, 491-492.	1.5	1
86	Self-administration of hospital-based narrowband ultraviolet B (TL-01) phototherapy: a feasibility study in an outpatient setting. British Journal of Dermatology, 2013, 169, 464-468.	1.5	8
87	Energy-saving lamps and their impact on photosensitive and normal individuals. British Journal of Dermatology, 2013, 169, 910-915.	1.5	14
88	Nine out of 10 sunbeds in England emit ultraviolet radiation levels that exceed current safety limits. British Journal of Dermatology, 2013, 168, 602-608.	1.5	24
89	A survey of photodynamic therapy services in dermatology departments across Scotland. Clinical and Experimental Dermatology, 2013, 38, 511-516.	1.3	8
90	Cytochrome P450 CYP1B1 Interacts with 8-Methoxypsoralen (8-MOP) and Influences Psoralen-Ultraviolet A (PUVA) Sensitivity. PLoS ONE, 2013, 8, e75494.	2.5	15

#	Article	IF	Citations
91	Characterization of a Human Keratinocyte HaCaT Cell Line Model to Study the Regulation of CYP2S1. Drug Metabolism and Disposition, 2012, 40, 283-289.	3.3	23
92	Ambulatory photodynamic therapy using low irradiance inorganic lightâ€emitting diodes for the treatment of nonâ€melanoma skin cancer: an open study. Photodermatology Photoimmunology and Photomedicine, 2012, 28, 235-239.	1.5	42
93	Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid?. Photodermatology Photoimmunology and Photomedicine, 2012, 28, 272-273.	1.5	9
94	Photodynamic therapy and immunosuppression. British Journal of Dermatology, 2012, 167, 465-467.	1.5	1
95	What is the role of photodynamic therapy in the treatment of acne vulgaris?. Photodiagnosis and Photodynamic Therapy, 2012, 9, 2-4.	2.6	6
96	Monte Carlo simulations for optimal light delivery in photodynamic therapy of non-melanoma skin cancer. Physics in Medicine and Biology, 2012, 57, 6327-6345.	3.0	26
97	Glutathione S-transferase genotype is associated with sensitivity to psoralen-ultraviolet A photochemotherapy. British Journal of Dermatology, 2012, 166, 380-388.	1.5	20
98	Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report. Clinical and Experimental Dermatology, 2012, 37, 219-226.	1.3	36
99	Role of nonâ€surgical therapies in the management of periocular basal cell carcinoma and squamous intraâ€epidermal carcinoma: a case series and review of the literature. Photodermatology Photoimmunology and Photomedicine, 2012, 28, 68-79.	1.5	20
100	Prevalence and predictors of low vitamin <scp>D</scp> status in patients referred to a tertiary photodiagnostic service: a retrospective study. Photodermatology Photoimmunology and Photomedicine, 2012, 28, 91-96.	1.5	13
101	What's new in photoimmunology?. Photodermatology Photoimmunology and Photomedicine, 2012, 28, 108-110.	1.5	0
102	A case of false-negative monochromator phototesting in a patient with chronic actinic dermatitis taking prednisolone. British Journal of Dermatology, 2012, 167, 214-215.	1.5	3
103	Modelling fluorescence in clinical photodynamic therapy. Photochemical and Photobiological Sciences, 2012, 12, 203-213.	2.9	39
104	A review of pain experienced during topical photodynamic therapyâ€"Our experience in Dundee. Photodiagnosis and Photodynamic Therapy, 2011, 8, 53-57.	2.6	38
105	Irradiance is an important determinant of pain experienced during topical photodynamic therapy. Journal of the American Academy of Dermatology, 2011, 65, 201-202.	1.2	12
106	Adverse effects of topical photodynamic therapy. Photodermatology Photoimmunology and Photomedicine, 2011, 27, 116-130.	1.5	78
107	Parameters associated with severe pain during photodynamic therapy: results of a large Scottish series. British Journal of Dermatology, 2011, 165, 696-698.	1.5	11
108	Oxygen saturation and perfusion changes during photodynamic therapy: use of noninvasive monitoring. British Journal of Dermatology, 2011, 165, 1158-1159.	1.5	0

#	Article	IF	Citations
109	Action spectrum for etofenamate photoallergic contact dermatitis. Contact Dermatitis, 2011, 65, 117-118.	1.4	12
110	Localized bullous pemphigoid induced by photodynamic therapy. Photodermatology Photoimmunology and Photomedicine, 2011, 27, 251-253.	1.5	32
111	A Quantitative Comparison of 5â€Aminolaevulinic Acidâ€•and Methyl Aminolevulinateâ€Induced Fluorescence, Photobleaching and Pain During Photodynamic Therapy. Photochemistry and Photobiology, 2011, 87, 242-249.	2.5	35
112	Monte Carlo modeling of in vivo protoporphyrin IX fluorescence and singlet oxygen production during photodynamic therapy for patients presenting with superficial basal cell carcinomas. Journal of Biomedical Optics, 2011, 16, 048002.	2.6	44
113	A Randomized Comparison of Methods of Selecting Narrowband UV-B Starting Dose to Treat Chronic Psoriasis. Archives of Dermatology, 2011, 147, 168.	1.4	19
114	Erythropoietic Uroporphyria Associated with Myeloid Malignancy Is Likely Distinct from Autosomal Recessive Congenital Erythropoietic Porphyria. Journal of Investigative Dermatology, 2011, 131, 1172-1175.	0.7	21
115	An overview of topical photodynamic therapy in dermatology. Photodiagnosis and Photodynamic Therapy, 2010, 7, 16-23.	2.6	43
116	Randomized Double-Blind Comparative Study of 8-Methoxypsoralen Bath Plus UV-A Treatment Regimens. Actas Dermo-sifiliogrÃ¡ficas, 2010, 101, 729-730.	0.4	1
117	Randomized Double-blind Comparative Study of 8-Methoxypsoralen Bath Plus UV-A Treatment Regimens. Actas Dermo-sifiliogrÃ¡ficas, 2010, 101, 729-730.	0.4	1
118	Photodynamic therapy and cancer. BMJ: British Medical Journal, 2009, 339, b2459-b2459.	2.3	3
119	Time course for development of psoralen plus ultraviolet A erythema following oral administration of 5-methoxypsoralen. British Journal of Dermatology, 2009, 160, 717-719.	1.5	2
120	An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer. British Journal of Dermatology, 2009, 161, 170-173.	1.5	139
121	How we treat Bowen's disease with topical photodynamic therapy in Dundee. Photodiagnosis and Photodynamic Therapy, 2009, 6, 41-45.	2.6	8
122	Within-patient right-left blinded comparison of diode (810Ânm) laser therapy and intense pulsed light therapy for hair removal. Lasers in Medical Science, 2008, 23, 393-397.	2.1	22
123	Does surface preparation alter ALA uptake in superficial nonâ€melanoma skin cancer in vivo?. Photodermatology Photoimmunology and Photomedicine, 2008, 24, 72-75.	1.5	27
124	A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8â€“20Âmm), with a 12â€month followâ€up.. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 1302-1311.	2.4	208
125	Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream. Journal of Dermatological Treatment, 2008, 19, 156-158.	2.2	15
126	A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. Journal of Dermatological Treatment, 2008, 19, 111-117.	2.2	27

#	Article	IF	Citations
127	Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. European Journal of Dermatology, 2008, 18, 547-53.	0.6	189
128	Can dietary furanocoumarin ingestion enhance the erythemal response during high-dose UVA1 therapy?. Journal of the American Academy of Dermatology, 2007, 56, 84-87.	1.2	12
129	A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. British Journal of Dermatology, 2007, 157, 401-403.	1.5	59
130	Late presentation of erythropoietic protoporphyria: case report and genetic analysis of family members. British Journal of Dermatology, 2007, 157, 1030-1031.	1.5	29
131	Melanocortin 1 receptor (MC1R) genotype influences erythemal sensitivity to psoralenâ€“ultraviolet A photochemotherapy. British Journal of Dermatology, 2007, 157, 1230-1234.	1.5	16
132	Acute phototoxicity with urticarial features during topical 5-aminolaevulinic acid photodynamic therapy. Clinical and Experimental Dermatology, 2007, 32, 201-202.	1.3	29
133	How we treat a superficial basal cell carcinoma with topical photodynamic therapy in Dundee. Photodiagnosis and Photodynamic Therapy, 2006, 3, 128-131.	2.6	6
134	Characteristics of 5-aminolaevulinic acid-induced protoporphyrin IX fluorescence in human skin in vivo. Photodermatology Photoimmunology and Photomedicine, 2006, 22, 105-110.	1.5	36
135	Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. British Journal of Dermatology, 2006, 154, 7-20.	1.5	108
136	Ambulatory photodynamic therapy: a new concept in delivering photodynamic therapy. British Journal of Dermatology, 2006, 154, 747-750.	1.5	62
137	Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo. British Journal of Dermatology, 2006, 155, 275-281.	1.5	39
138	Photopatch testing of 1155 patients: results of the U.K. multicentre photopatch study group. British Journal of Dermatology, 2006, 155, 737-747.	1.5	127
139	Abstract No. 3â€˜Is there a skin cancer risk with narrowband ultraviolet B phototherapy? Preliminary data from the second phase of the Dundee follow-up study. British Journal of Dermatology, 2006, 155, 866-867.	1.5	3
140	UVA1 phototherapy for treatment of necrobiosis lipoidica. Clinical and Experimental Dermatology, 2006, 31, 235-238.	1.3	47
141	UVA1 phototherapy for genital lichen sclerosus. Clinical and Experimental Dermatology, 2006, 31, 343-347.	1.3	62
142	Clinical and research applications of photodynamic therapy in dermatology: Experience of the scottish PDT centre. Lasers in Surgery and Medicine, 2006, 38, 403-416.	2.1	52
143	Comparison of Topical Methyl Aminolevulinate Photodynamic Therapy With Cryotherapy or Fluorouracil for Treatment of Squamous Cell Carcinoma In Situ. Archives of Dermatology, 2006, 142, 729-35.	1.4	215
144	CK2-site Phosphorylation of p53 is Induced in Î”Np63 Expressing Basal Stem Cells in UVB Irradiated Human Skin. Cell Cycle, 2006, 5, 2489-2494.	2.6	22

#	Article	IF	Citations
145	Carbamazepine-Induced Hypersensitivity Syndrome Occurring in a Photodistributed Pattern. Dermatology, 2006, 213, 166-168.	2.1	8
146	Chronic actinic dermatitis. Expert Review of Dermatology, 2006, 1, 451-461.	0.3	5
147	Dose-Response and Time-Course Characteristics of UV-A1 Erythema. Archives of Dermatology, 2005, 141, 1549-55.	1.4	25
148	The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. British Journal of Dermatology, 2005, 152, 755-757.	1.5	129
149	The effect of ultraviolet (UV) A1, UVB and solar-simulated radiation on p53 activation and p21Waf1/Cip1. British Journal of Dermatology, 2005, 152, 1001-1008.	1.5	22
150	A randomized controlled comparison of the efficacy of Dead Sea salt balneophototherapy vs. narrowband ultravioletâ€ƒB monotherapy for chronic plaque psoriasis. British Journal of Dermatology, 2005, 153, 613-619.	1.5	31
151	Differential effects of 5-aminolaevulinic acid photodynamic therapy and psoralen + ultraviolet A therapy on p53 phosphorylation in normal human skin in vivo. British Journal of Dermatology, 2005, 153, 1001-1010.	1.5	26
152	Can St John's wort (hypericin) ingestion enhance the erythemal response during high-dose ultraviolet A1 therapy?. British Journal of Dermatology, 2005, 153, 1187-1191.	1.5	22
153	Woringer-Kolopp (localized pagetoid reticulosis) treated with topical photodynamic therapy (PDT). Clinical and Experimental Dermatology, 2005, 30, 446-447.	1.3	14
154	Does narrow-band ultraviolet B phototherapy work in atopic dermatitis through a local or a systemic effect?. Photodermatology Photoimmunology and Photomedicine, 2005, 21, 333-335.	1.5	7
155	A randomised, blinded, controlled study of the clinical relevance of matching pulse duration to thermal relaxation time when treating facial telangiectasia. Lasers in Medical Science, 2005, 20, 117-121.	2.1	11
156	Photogenotoxicity of hypericin in HaCaT keratinocytes: Implications for St. John's Wort supplements and high dose UVA-1 therapy. Toxicology Letters, 2005, 158, 220-224.	0.8	27
157	The Development of a CDK2-Docking Site Peptide that Inhibits p53 and Sensitizes Cells to Death. Cell Cycle, 2004, 3, 79-88.	2.6	18
158	A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (AmetopR) for pain relief during topical photodynamic therapy. British Journal of Dermatology, 2004, 150, 337-340.	1.5	91
159	A pilot study of treatment of lentigo maligna with 5% imiquimod cream. British Journal of Dermatology, 2004, 151, 485-488.	1.5	99
160	The optimal time to determine the minimal phototoxic dose in skin photosensitized by topical 8 methoxypsoralen. British Journal of Dermatology, 2004, 151, 179-182.	1.5	12
161	Co-existence of chronic actinic dermatitis and solar urticaria in three patients. British Journal of Dermatology, 2004, 151, 513-515.	1.5	11
162	An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. British Journal of Dermatology, 2004, 151, 283-297.	1.5	243

#	Article	IF	Citations
163	Narrow-band (TL-01) ultraviolet B phototherapy for chronic urticaria. Clinical and Experimental Dermatology, 2004, 29, 97-98.	1.3	43
164	Lack of efficacy and tolerability of topical PDT for psoriasis in comparison with narrowband UVB phototherapy. Clinical and Experimental Dermatology, 2004, 29, 560-562.	1.3	34
165	Photopatch testing: a consensus methodology for Europe. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 679-682.	2.4	160
166	The characteristics of erythema induced by topical 5-aminolaevulinic acid photodynamic therapy. Photodermatology Photoimmunology and Photomedicine, 2004, 20, 105-107.	1.5	17
167	Can a positive photopatch test be elicited by subclinical irritancy or allergy plus suberythemal UV exposure?. Contact Dermatitis, 2004, 51, 235-240.	1.4	9
168	Treatment of superficial cutaneous vascular lesions: experience with the KTP 532ï¿½nm laser. Lasers in Medical Science, 2004, 19, 1-5.	2.1	78
169	Photodynamic therapy in dermatology: Dundee clinical and research experience. Photodiagnosis and Photodynamic Therapy, 2004, 1, 211-223.	2.6	23
170	Photoinduced pompholyx: a report of 5 cases. Journal of the American Academy of Dermatology, 2004, 50, 55-60.	1.2	22
171	Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatology Photoimmunology and Photomedicine, 2003, 19, 134-141.	1.5	142
172	Quantitative Real-Time Reverse Transcriptionâ€“Polymerase Chain Reaction Analysis of Drug Metabolizing and Cytoprotective Genes in Psoriasis and Regulation by Ultraviolet Radiation. Journal of Investigative Dermatology, 2003, 121, 390-398.	0.7	48
173	A randomized controlled trial of narrowband ultraviolet B vs. bath-psoralen plus ultraviolet A photochemotherapy for psoriasis. British Journal of Dermatology, 2003, 148, 1194-1204.	1.5	63
174	Milia complicating photocontact allergy to absorbent sunscreen chemicals. Clinical and Experimental Dermatology, 2003, 28, 668-669.	1.3	7
175	A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. British Journal of Dermatology, 2003, 149, 1232-1241.	1.5	81
176	Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet, The, 2003, 361, 1336-1343.	13.7	137
177	An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5?, 8-trimethylpsoralen. Journal of the American Academy of Dermatology, 2003, 49, 59-64.	1.2	13
178	An Intraindividual Study of the Characteristics of Erythema Induced by Bath and Oral Methoxsalen Photochemotherapy and Narrowband Ultraviolet BÂ¶. Photochemistry and Photobiology, 2003, 78, 55.	2.5	16
179	Characteristics and Prognosis of Idiopathic Solar Urticaria. Archives of Dermatology, 2003, 139, 1149-54.	1.4	133
180	The Time Course of Topical PUVA Erythema Following 15- and 5-Minute Methoxsalen Immersion. Archives of Dermatology, 2003, 139, 331-4.	1.4	13

#	Article	IF	Citations
181	An Intraindividual Study of the Characteristics of Erythema Induced by Bath and Oral Methoxsalen Photochemotherapy and Narrowband Ultraviolet BÂ¶. Photochemistry and Photobiology, 2003, 78, 55-60.	2.5	16
182	UV-B Phototherapy Clears Psoriasis Through Local Effects. Archives of Dermatology, 2002, 138, 1071-6.	1.4	37
183	Time course of PUVA erythema. Journal of Dermatological Treatment, 2002, 13, 179-184.	2.2	0
184	008ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½The time-course of TL-01 UVB erythema. Photodermatology Photoimmunology and Photomedicine, 2002, 18, 105-105.	1.5	2
185	Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. British Journal of Dermatology, 2002, 146, 178-188.	1.5	97
186	Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. British Journal of Dermatology, 2002, 146, 552-567.	1.5	444
187	Guidelines for dosimetry and calibration in ultraviolet radiation therapy: a report of a British Photodermatology Group workshop. British Journal of Dermatology, 2002, 146, 755-763.	1.5	67
188	A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. British Journal of Dermatology, 2002, 147, 973-978.	1.5	107
189	Sun awareness and behaviour in healthcare professionals and the general public. Clinical and Experimental Dermatology, 2002, 27, 442-444.	1.3	8
190	Spontaneous resolution of chronic actinic dermatitis in a young patient with atopic dermatitis. Clinical and Experimental Dermatology, 2002, 27, 163-164.	1.3	5
191	30th Annual General Meeting Aberdeen 2-3 June 2000. Clinical and Experimental Dermatology, 2002, 27, 252-252.	1.3	1
192	The Effect of Methoxsalen Dose on Ultraviolet-A-Induced Erythema. Journal of Investigative Dermatology, 2001, 116, 813-815.	0.7	11
193	The Application of a Compact Multispectral Imaging System with Integrated Excitation Source to In vivo Monitoring of Fluorescence During Topical Photodynamic Therapy of Superficial Skin CancersÂ¶. Photochemistry and Photobiology, 2001, 73, 278-282.	2.5	40
194	Experimental contact sensitivity in patients with previous exposure to high-dose puva photochemotherapy. Archives of Dermatology, 2001, 137, 381-3.	1.4	0
195	The application of a compact multispectral imaging system with integrated excitation source to in vivo monitoring of fluorescence during topical photodynamic therapy of superficial skin cancers. Photochemistry and Photobiology, 2001, 73, 278-82.	2.5	7
196	Guidelines for topical PUVA: a report of a workshop of the British Photodermatology Group. British Journal of Dermatology, 2000, 142, 22-31.	1.5	111
197	The review of the public health function in Scotland: implications for the National Health Service. Health Bulletin, 2000, 58, 81-6.	0.1	0
198	The Time-Course of Psoralen Ultraviolet A (PUVA) Erythema. Journal of Investigative Dermatology, 1999, 113, 346-349.	0.7	49

#	Article	IF	Citations
199	Non-Langerhans cell histiocytosis associated with lymphocyte-predominant Hodgkin's disease. Clinical and Experimental Dermatology, 1999, 24, 365-367.	1.3	4
200	The Effects of Radicals Compared with UVB as Initiating Species for the Induction of Chronic Cutaneous Photodamage. Journal of Investigative Dermatology, 1999, 112, 933-938.	0.7	27
201	The idiopathic photodermatoses. Seminars in Cutaneous Medicine and Surgery, 1999, 18, 257-273.	1.6	22
202	Benzoyl Peroxide Increases UVA-Induced Plasma Membrane Damage and Lipid Oxidation in Murine Leukemia L1210 Cells. Journal of Investigative Dermatology, 1998, 110, 79-83.	0.7	11
203	The relevance and effect of amalgam replacement in subjects with oral lichenoid reactions. British Journal of Dermatology, 1996, 134, 420-423.	1.5	31
204	The effect of topical indomethacin on ultraviolet-radiation-induced erythema. British Journal of Dermatology, 1996, 135, 523-527.	1.5	8
205	Milia as unusual sequelae to allergic contact dermatitis. Contact Dermatitis, 1996, 35, 49-50.	1.4	9
206	Episodic vasculitis of the hands and feet in association with BehÃ§et's disease. Clinical and Experimental Dermatology, 1996, 21, 465-466.	1.3	2
207	The relevance and effect of amalgam replacement in subjects with oral lichenoid reactions. British Journal of Dermatology, 1996, 134, 420-3.	1.5	7
208	The effect of topical indomethacin on ultraviolet-radiation-induced erythema. British Journal of Dermatology, 1996, 135, 523-7.	1.5	4
209	Acute severe bronchoconstriction precipitated by coal tar bandages. Clinical and Experimental Dermatology, 1995, 20, 58-59.	1.3	4
210	Adhesion molecules in inflammatory bowel disease.. Gut, 1995, 36, 724-730.	12.1	178
211	The effect of aspirin on haemostatic activity in the treatment of chronic venous leg ulceration. British Journal of Dermatology, 1995, 132, 422-426.	1.5	54
212	Reduced experimental contact sensitivity in squamous cell but not basal cell carcinomas of skin. Lancet, The, 1995, 345, 425-426.	13.7	17
213	Do we need pigmented lesion clinics?. Lancet, The, 1995, 346, 1373.	13.7	4
214	An uninvolved pregnancy in a patient after a previous episode of herpes gestationis. Archives of Dermatology, 1995, 131, 1091-1092.	1.4	11
215	An uninvolved pregnancy in a patient after a previous episode of herpes gestationis. Archives of Dermatology, 1995, 131, 1091-2.	1.4	2
216	The effect of insulin-induced hypoglycaemia on factor VIII:C concentrations and thrombin activity in subjects with type 1 (insulin-dependent) diabetes. Thrombosis and Haemostasis, 1995, 73, 243-6.	3.4	7

#	Article	IF	Citations
217	Allergic contact dermatitis from aziridine crosslinker cx 100. Contact Dermatitis, 1994, 30, 306-307.	1.4	12
218	Follicular keratoses at amputation sites. British Journal of Dermatology, 1994, 130, 770-772.	1.5	44
219	Plasminogen activator inhibitor 1 (PAI-1) levels in patients with chronic venous leg ulceration. British Journal of Dermatology, 1994, 131, 738-738.	1.5	6
220	Randomised trial of oral aspirin for chronic venous leg ulcers. Lancet, The, 1994, 344, 164-165.	13.7	108
221	The effect of short-term exercise on plasma procoagulant activity in patients with type II (non-insulin-dependent) diabetes and healthy volunteers. Thrombosis Research, 1993, 71, 149-158.	1.7	7
222	Thrombin Generation and Factor VIII:C Levels in Patients with Type 1 Diabetes Complicated by Nephropathy. Diabetic Medicine, 1993, 10, 336-340.	2.3	7
223	Generation of thrombin activity in relation to factor VIII: C concentrations and vascular complications in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1992, 35, 863-867.	6.3	11
224	Thrombin Activity by Intrinsic Activation of Plasma In-Vitro Accelerates with Increasing Age of the Donor. Thrombosis and Haemostasis, 1992, 67, 377-380.	3.4	19
225	Thrombin activity by intrinsic activation of plasma in-vitro accelerates with increasing age of the donor. Thrombosis and Haemostasis, 1992, 67, 377-80.	3.4	4
226	The Influence of Infusions of 1-Desamino-8-D-Arginine vasopressin (DDAVP) In Vivo on the Anticoaguhht Effect of Recombinant Hirudin (CGP39393) In Vitro. Thrombosis and Haemostasis, 1991, 65, 064-066.	3.4	33
227	Influence of Increasing Levels of High Purity Factor VIII on Thrombin Generation In-Vitro. Clinical Science, 1990, 79, 15P-15P.	0.0	3
228	Phototherapy for atopic eczema. The Cochrane Library, 0, , .	2.8	4